Rebecca C.Martin

Partner

New York + 1.212.326.3410

Rebecca Martin is experienced in civil and criminal investigations and litigations involving the False Claims Act (FCA); Financial Institutions Reform, Recovery and Enforcement Act (FIRREA); Anti-Kickback Statute (AKS); Food, Drug and Cosmetics Act (FDCA); and other health care and financial matters. Her clients include commercial lenders, medical device and diagnostic companies, digital and telemedicine health providers, academic medical centers and hospitals, post-acute facilities, multistate physician practices, and private equity sponsors and portfolio companies in the fintech and health care sectors. Rebecca has obtained highly favorable results in litigations and government investigations in FCA and other matters. A recognized thought leader in the field, Rebecca writes and speaks regularly regarding FCA and fraud and abuse issues.

Rebecca is a 15-year veteran of the United States Attorney's Office for the Southern District of New York (SDNY), where she served as co-chief of the Civil Frauds Unit and health care fraud coordinator. As co-chief, she was responsible for a full range of matters involving FCA and FIRREA, which resulted in billions of dollars in recoveries for the government during her tenure. Rebecca's portfolio included the financial, health care, pharmaceutical, research, and government contracting industries.

As co-chief, Rebecca supervised and handled groundbreaking FCA and FIRREA cases involving mortgage origination and securitization and a wide range of AKS and other matters in hospital/provider, pharmaceutical, pharmacy, and university settings. Rebecca's work involved extensive coordination with multiple components of the Department of Justice (DOJ), FBI, Department of Housing and Urban Development (HUD), Department of Health and Human Services/Office of Inspector General, National Institutes of Health, TRICARE, and other federal agencies.

Speaking Engagements

  • August 2020
    Compliance Round-Up: City Bar Series on COVID-19’s Impact on Ethics and Compliance: COVID-19 Lending Programs: Latest Developments (New York City Bar)
  • April 2020
    Is the Tsunami Coming? Potential Litigation and Regulatory Risks for Lenders under the Recently Enacted Covid-19 Loan Programs (New York City Bar Webinar)
  • January 2020
    Analyzing the Government’s Evaluation of a Qui Tam Action (6th Annual Advanced Forum on False Claims & Qui Tam Enforcement)
  • September 2019
    False Claims Act and Healthcare Fraud (2019 American Bar Association Healthcare Delivery and Innovation Conference)
  • May 2019
    Critical Legal Issues (2019 Physician Practice Management and ASC Symposium)
  • January 2019
    How DOJ Decides When to Intervene and an Update on Criminal/Civil Concurrent Investigations (5th Annual Advanced Forum on False Claims & Qui Tam Enforcement)
  • July 2017
    Whistleblowing and Recent Developments, National Society for Corporate Governance, The Golden State of Governance Annual Conference, San Francisco
  • January 2017
    False Claims Act Enforcement Trends, Practicing Law Institute Annual Conference
  • November 2016
    Self-Disclosures: When, Where and How, Health Care Investigations and Litigation, (November 2016)
  • November 2016
    Navigating Legal Challenges, PLI Life Science Conference
  • September 2016
    Reverse False Claims and the 60-Day Rule, HCCA Boston Regional Annual Compliance Conference
  • October 2014
    Enforcement Trends, Practising Law Institute’s Health Care and Life Sciences Law 2014
  • September 2014
    Program Integrity and Enforcement: The Government Perspective, NYSBA, Health Law Section
  • January 2014
    Law Enforcement Panel, CBI Pharmaceutical Compliance Congress
We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.